GLIOMATCH is a Horizon Europe project dedicated to pioneering targeted treatments for brain cancer. Led by KU Leuven, the project brings together more than a dozen partners from ten EU member states to advance personalised medicine for one of the most lethal cancer types. In line with Europe’s Beating Cancer Plan, GLIOMATCH contributes to the EU Cancer Mission’s objectives through the ‘Understanding (Tumour-Host) Interactions’ Cluster. By making technology for customised treatments accessible to clinicians, GLIOMATCH aims to relieve the burden brain tumours place on patients, families, and healthcare systems across Europe.
Find out more about the GLIOMATCH project by watching our explainer video. In the video, Prof. Frederik De Smet (KUL), GLIOMATCH project coordinator, breaks down the project’s objectives, innovation, and overall structure.
In this GLIOMATCH: Explained episode, Prof. Dr. Steven De Vleeschouwer introduces the prospective clinical trials, the participating centres and the immunotherapy strategies being investigated to better understand patient response in brain tumours.
On 28–29 April 2026, the GLIOMATCH consortium gathered in Barcelona, Spain, for its fifth consortium meeting, hosted by project partner Sant Joan de Déu Barcelona Children’s Hospital and the Fundació de Recerca Sant Joan de Déu (FSJD).
GLIOMATCH joined partners of the Understanding (tumour-host interactions) Cluster – an initiative of the EU’s Cancer Mission – in Warsaw in March 2026 to review scientific progress, strengthen collaboration and advance joint work on data management and policy-relevant research.
